Three deaths in China’s investigator-initiated trials raise concerns over fast, low-cost clinical testing

Three participants died while taking part in investigator-initiated trials in China, prompting renewed scrutiny of the country’s clinical testing practices.

China’s system is prized for its low cost, rapid timelines and relative quiet, drawing developers of cutting‑edge cell and gene therapies to conduct studies there.

The fatalities have sparked calls for tighter oversight, raising doubts among sponsors and investors about the reliability of the fast‑track approach and could lead to stricter regulatory requirements.